Arctic Bioscience AS · OSL:ABS
Arctic Bioscience AS — Q3 2026 Earnings Presentation
32 slides from Arctic Bioscience AS's earnings presentation, Nov 11, 2026
Slide 1: Arctic Bioscience Q3 2026 update
Arctic Bioscience Pioneers in natural resolution of inflammation Presentation of financial results; Q3 2026 update November 11th 2026 Christer L. Valderhaug (CEO) Runhild Gammelsæter (Medical Director) Jone R. Slinning (CFO)
Slide 2: Disclaimer
Disclaimer Matters discussed in this correct, and their methodology ascertain from the information Presentation may constitute or may be forward-looking and published by that third party, no include forward-looking speculative. facts have been omitted that statements. Forward-looking would render th
Slide 3: Developing and commercializing pharmaceutical and nutraceutical products
Developing and commercializing pharmaceutical and nutraceutical products based on unique bioactive marine compounds, utilizing proprietary technology and methodology
Slide 4: Agenda
Agenda Operational highlights Operational review Nutra Operational review Pharma Q3-2026 consolidated Group financial review Business outlook Q&A
Slide 5: Intro and Q3-2026 operational highlights
Intro and Q3-2026 operational highlights 5
Slide 6: 2026 Q3 highlights
2026 Q3 highlights HRO350 inflammation data sharpen the path forward Phase III design, EMA scientific advice and partnership discussions are the next steps Nutra revenue +26% Americas revenue +101% B2B revenue +31% NOK 32.6m in the first nine months of 2026, NOK 14.9m in the first nine months, NOK 2
Slide 7: Operational review Nutra
Operational review Nutra 7
Slide 8: Nutra growth continued in Q3
Nutra growth continued in Q3 NINE MONTHS TO 30 SEPTEMBER 2026 THIRD QUARTER NOK 32.6m NOK 9.3m Approximately 7% growth +26% year on year Q3 2025 revenue: NOK 8.7m NOK 25.9m in the same period of 2025 Supplier delivery delays continued to affect revenue timing Growth moderated from 35.2% in H1. The o
Slide 9: B2B drives growth and a larger share of sales
B2B drives growth and a larger share of sales NUTRA REVENUE BY CHANNEL, NOK MILLION 35 +31% y/y 29,2 30 B2B revenue growth to NOK 29.2m 25 22,3 20 B2C revenue: NOK 3.4m 15 10 Down 5.8% year on year The B2C plan prioritises existing customers 5 3,6 3,4 and lower marketing spend 0 B2B B2C 9M 2025 9M 2
Slide 10: Americas revenue doubled and leads the sales mix
Americas revenue doubled and leads the sales mix NUTRA REVENUE BY REGION, NOK MILLION 18 +101% 16 14,9 Americas revenue reached NOK 14 14.9m, or 46% of Nutra sales 12 10 9,3 9,1 8 7,4 APAC grew 15% to NOK 4.4m 6 5,4 Europe was broadly stable 4,2 4,4 Norway declined 22% 3,8 4 2 0 Norway Europe Americ
Slide 11: Bevimi customer story: ROMEGA in Uno Protect
Bevimi customer story (US): ROMEGA® in Uno Protect OCTOBER 2026 DEVELOPMENT Up to US$2m A daily liquid brain- Bevimi selected for ARPA-H research health supplement funding containing ROMEGA® phospholipids 150 adults Planned 24-week randomized, double-blind, placebo-controlled study of early cognitiv
Slide 12: Napiers customer story: Arctic Omega-3
Napiers customer story: Arctic Omega-3 NAPIERS THE HERBALISTS (UK) Arctic Omega-3 Napiers offers Norwegian herring caviar oil in its Arctic Omega-3 supplement - containing ROMEGA® phospholipids. Launched Aug/Sept
Slide 13: NeuroReserve customer story: second ROMEGA product
NeuroReserve customer story: second ROMEGA® product US CUSTOMER REO3 NeuroReserve has launched its second ROMEGA®-based product, using ROMEGA®-30 Premium The US brand positions REO3 around phospholipid omega-3 DHA and EPA, with specialized pro-resolving mediators (SPMs)
Slide 14: Genstory customer story: ROMEGA launches in South Korea
Genstory customer story: ROMEGA® launches in South Korea REGIONAL PARTNER Genstory Partner for Singapore and South Korea Recent South Korean launch brings ROMEGA® to the Coupang marketplace Premium, Eye Premium and Skin Refine listed on the Korean marketplace
Slide 15: Commercial, product and operational development priorities
Commercial-, product- and operational development priorities International B2B Support recurring customers and further develop Commercial focus new US customers and APAC partner channels. Several new international Brand-launches upcoming Product portfolio Adapt product formulations and applications
Slide 16: Operational review Pharma
Operational review Pharma 16
Slide 17: Pharmaceutical pipeline and overall status
Pharmaceutical pipeline and overall status ABS302 HRO350 ABS403 Brain development in Mild to moderate Psoriasis Glaucoma extremely premature infants Status Status Status • Phase 2b study completed • Successful formulation of two liquid • Successful clinical pilot study • Significant results on syste
Slide 18: HRO350
HRO350 Mild-to-moderate psoriasis
Slide 19: HRO350: Beyond topicals, before biologics
HRO350: Beyond topicals, before biologics HRO350 is an investigational medicinal product currently with phase 2b data in mild-to-moderate psoriasis
Slide 20: HeROPA data publication plan H2 2026
HeROPA data publication plan H2 2026 Publication STATUS NOV DEC Published (peer-review) Herring roe PLs promote SPM biosynthesis in macrophages and a https://www.jlr.org/article/S0022-2275(26)00042- keratinocyte/fibroblast coculture as a model of psoriasis 8/fulltext Published (peer-review) Herring
Slide 21: Timeline toward phase 3 and partnering
Timeline toward phase 3 and partnering November 5–7 April 2027 7–10 June 2027 Estimated start Scientific Advice BIOEurope BIOInternational procedure Lyon Philadelphia Estimated duration: 2–3 months Publications will coincide with the Scientific Advice submission
Slide 22: ABS403
ABS403 Glaucoma
Slide 23: Future Directions for ABS403
Future Directions for ABS403: Bioavailable with anti-inflammatory properties ABS403 in the resolution of inflammation • Bioavailable phospholipid-based treatment • Crosses the blood-brain and blood-retinal barrier • in vitro data from human immune cells and lipid mediators Future development of ABS4
Slide 24: ABS302
ABS302 Extremely premature infants
Slide 25: Extremely premature infants (ABS302)
Extremely premature infants (ABS302) • Being developed with Smerud Medical Research International • European consortium established for pre-clinical studies (efficacy and toxicology) • Prenatal departments at Inserm (France), Giannina Gaslini Institute (Italy), Lund and Gøteborg Hospitals (Sweden) •
Slide 26: Q3-2026 consolidated group financial review
Q3-2026 consolidated group financial review 26
Slide 27: Key financial figures
Key financial figures SALES REVENUES GROSS MARGIN AVAILABLE LIQUIDITY 32,6 39,7% 7,5 32,6% 25,9 29,4% 5,2 21,6% 8,7 9,3 1,4 Q3-2025 Q3-2026 YTDQ3-25 YTDQ3-26 Q3-2025 Q3-2026 YTDQ3-25 YTDQ3-26 30.09.2025 31.12.2025 30.09.2026
Slide 28: EBITDA results
EBITDA results TNOK YTDQ3-26 YTDQ3-25 Strong 26 % year-on-year sales revenue growth • The American market +100 % growth compared to YTD Q3-25 Total revenue 34 824 28 385 • Delays in deliveries from sub-suppliers are still affecting timing of Sales rev enue 32 558 25 945 our sales revenues Other inco
Slide 29: Business outlook
Business outlook 29
Slide 30: Customer launches support the Nutra growth outlook
Customer launches support the Nutra growth outlook 01 COMMERCIAL SCALE 02 SUPPLY POSITION 03 PHARMA & CAPITAL GROW DIFFERENTIATE DE-RISK Robust order pipeline and Strategic positioning and product Additional HeROPA publications recurring customers support differentiation are becoming should expand v
Slide 31: Arctic Bioscience
ARCTIC Bioscience
Slide 32: Contact
Contact CEO - Christer L. Valderhaug: christer@arctic-bioscience.com CFO - Jone R. Slinning jone@arctic-bioscience.com Medical Director - Runhild Gammelsæter: runhild@arctic-bioscience.com Subscribe to news www.arctic-bioscience.com/investors/home